# A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Source: https://onco.cc/trials/nct06623422/  
OnCo record `nct06623422` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Intismeran autogene in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) is a phase 3 interventional study registered as NCT06623422 by Merck Sharp & Dohme LLC, with 680 participants planned, started 2024-10-21 and due to reach its primary completion in 2033-05-16. Interventions recorded: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06623422
- Phase: 3
- Setting: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 680

## Sources

- ClinicalTrials.gov NCT06623422: https://clinicaltrials.gov/study/NCT06623422

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06623422.json